Citizens Jmp Issues Positive Forecast for Progyny (NASDAQ:PGNY) Stock Price

Progyny (NASDAQ:PGNY) had its target price increased by Citizens Jmp from $33.00 to $38.00 in a report issued on Thursday,Benzinga reports. The firm currently has a market outperform rating on the stock.

Several other analysts also recently commented on PGNY. Leerink Partners set a $38.00 price objective on Progyny in a research note on Wednesday, July 22nd. Zacks Research downgraded Progyny from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 19th. BTIG Research boosted their target price on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday, July 24th. KeyCorp upped their price target on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Barclays decreased their price target on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 12th. Eleven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.92.

Progyny Stock Performance

NASDAQ PGNY opened at $34.37 on Thursday. The firm has a market cap of $2.64 billion, a PE ratio of 31.53, a P/E/G ratio of 2.08 and a beta of 0.97. Progyny has a one year low of $16.10 and a one year high of $35.50. The firm’s fifty day moving average is $27.27 and its two-hundred day moving average is $24.54.

Progyny (NASDAQ:PGNY) last announced its earnings results on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.23%. The business had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. During the same period in the prior year, the company earned $0.15 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. Research analysts predict that Progyny will post 1.25 earnings per share for the current year.

Insider Transactions at Progyny

In related news, COO Melissa Cummings sold 1,879 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total transaction of $52,612.00. Following the transaction, the chief operating officer owned 66,496 shares of the company’s stock, valued at approximately $1,861,888. This represents a 2.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the transaction, the executive vice president owned 75,816 shares in the company, valued at $1,978,797.60. This trade represents a 4.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,282 shares of company stock worth $475,790 over the last ninety days. 9.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Progyny

Several hedge funds have recently modified their holdings of PGNY. Toth Financial Advisory Corp raised its stake in shares of Progyny by 21.3% during the third quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock valued at $69,000 after purchasing an additional 480 shares during the period. Oregon Public Employees Retirement Fund lifted its position in shares of Progyny by 4.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 17,254 shares of the company’s stock worth $435,000 after purchasing an additional 700 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Progyny in the 2nd quarter valued at approximately $29,000. State of Wyoming increased its stake in Progyny by 3.5% during the third quarter. State of Wyoming now owns 29,806 shares of the company’s stock valued at $751,000 after purchasing an additional 1,015 shares during the last quarter. Finally, Nykredit A S bought a new stake in shares of Progyny during the 2nd quarter valued at about $38,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny News Summary

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share, above analysts’ estimates, while revenue of $341.25 million slightly exceeded forecasts and rose 8.9% year over year. The company also highlighted record quarterly results. Third-quarter results
• Positive Sentiment: Progyny raised its full-year 2026 earnings guidance, signaling improved expectations for the year. The company also issued fourth-quarter guidance. 2026 guidance update
• Positive Sentiment: Analysts responded favorably: Citizens JMP raised its target from $33 to $38 and maintained a Market Outperform rating, while Leerink Partners raised its target from $37 to $38 with an Outperform rating. Cantor Fitzgerald also lifted its target from $31 to $35 and maintained Overweight. Citizens price-target update
• Neutral Sentiment: One Q3 analysis noted new client wins and margin expansion but described the market response as cautious, suggesting investors may be weighing the strong results against the company’s outlook and execution ahead. Q3 analysis

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.